Neuroendocrine Carcinoma Market

Neuroendocrine Carcinoma Market: Targeted Therapy Projected to be the Fastest Growing Segment by Treatment Type Through 2027: Global Industry Analysis (2012-2016) and Opportunity Assessment (2017-2027)

Ask The Analyst Customization Available Request Methodology

Rapid pace of cancer research and continuous product approvals for neuroendocrine tumours is expected to drive the growth of global neuroendocrine carcinoma market

The global neuroendocrine carcinoma market is anticipated to witness healthy growth throughout the period of forecast. The emergence of cancer led to an increase in the research activities for cancer which resulted in the development of carious therapeutic solutions with a view to treat cancer. This market report deals with various treatment types used in curing cancer and has been witnessing a positive growth path since past several years. The global neuroendocrine carcinoma market is projected to grow at a robust CAGR of 7.7% during the assessment period to reflect a 2x increase in revenue growth from 2017 till 2027. By the end of the assessment year (2027), the global neuroendocrine carcinoma market is estimated to reach a value of about US$ 2.5 Bn from an estimation of US$ 1.5 Bn in 2017. The global market has gained high steam since 2012 and developments in this market have been significantly improved ever since.

Opportunities grow strong for somatostatin analogs

The somatostatin analogs segment by treatment type is expected to witness high traction in the coming years. The use of somatostatin analogs in treating neuroendocrine cancer has experienced a significant growth with respect to market share since the 2012-2016 period. In 2017, this segment reflected an estimation of US$ 728.3 which is higher than any other segment or sub segment in the treatment type category. This trend is likely to continue over the coming years, thus making somatostatin analogs segment to reflect a high market share and valuation by 2027 end. This segment is likely to dominate the global market with a high estimation of around US$ 1.5 Bn by the end of the assessment period.

Both tyrosine kinase inhibitor and mTOR inhibitor to potentially contribute to the growth of targeted therapy

The targeted therapy segment is also expected to show high potential owing to high adoption. This segment is the second largest in terms of value and is projected to be the fastest growing segment to register a higher CAGR of 8.0% throughout the period of assessment 2017-2027. The targeted therapy segment is further segmented by tyrosine kinase inhibitor and mTOR inhibitor. The tyrosine kinase inhibitor sub segment is estimated to reflect a higher market share than the latter and is likely to lead the market highly contributing to the growth of the targeted therapy segment. On the other hand, the mTOR inhibitor sub segment is expected to gain higher pace in the coming years. During the 2017-2027 timeline this sub segment is projected to reach a high 8.5% CAGR to further push the growth of the targeted therapy segment in the years to come.

neuroendocrine carcinoma market

Chemotherapy to show a robust growth rate yet enjoys little market share

Chemotherapy segment, another treatment type dealing with neuroendocrine carcinoma, is expected to grow at robust growth rate throughout the period of assessment. This segment however, reflects less market value and is estimated to reach a valuation of about US$ 344 Mn by the end of the forecasted year growing at a noteworthy CAGR of 7.6%. The growth of the chemotherapy segment is significantly pushed by antimetabolites, alkylating agents and natural products sub segments. Of these, antimetabolites sub segment is expected to be highly lucrative and is the largest segment with respect to market value. The natural products sub segment is poised to grow at a comparatively higher CAGR of 7.8% throughout the period of forecast, 2017-2027.

Future Market Insights has revealed various facts on the neuroendocrine carcinoma market in its recently published research report titled “Neuroendocrine Carcinoma Market: Global Industry Analysis (2012-2016) and Opportunity Assessment (2017-2027)”. This research study is filled with incisive market insights and essential acumen and reflects various factors that have contributed to the growth of the global market. Along with the past market scenario, a glimpse of the future of the neuroendocrine carcinoma market is also portrayed. The forecast analysis is for five years, from 2017 to 2022. This can assist the reader in slating important strategies based on present market conditions to achieve expansion in the coming future.

A 3600 view of the entire market

Research study on neuroendocrine carcinoma market puts forth a global 3600 perspective. Main geographies across the entire globe are assessed and the trends, developments, opportunities, drivers and challenges in each region and sub region that have an influence over the growth of the market in the respective region are studied to get a clear picture of the global endocrine carcinoma market. Revenue pockets can be derived with such kind of intense market intelligence which is unbiased in nature and purely market centric thus portraying a global perspective in front of the reader.

Unparalleled research methodology for a unique research study

Future Market Insights follows a one of a kind research methodology to glean vital and relevant market insights. This research process ensures delivery of statistical data without errors, thus maximizing the accuracy of the research report. Secondary research in combination with primary research gives a clear market understanding based on which key players, market observers and opinion leaders are interviewed to check the reliability of the data and to add other facets of the market. The uniqueness of this research process is the revalidation and re-evaluation of the data that takes place at each step during each interview and is continued till the conclusion of the market research. Based on these vital acumen, key analysis can be drawn and recommendations from domain experts are included in this intelligence report. The multiple cross checking of the data ensures a highly accurate market scenario which can be directly used by the reader to chalk informed decisions.

Market Segmentation

The global research report on neuroendocrine carcinoma market includes an in-depth analysis on each segment of the entire market. The market segmentation covers disease indication type, end user, treatment type and region.

By Disease Indication Type

By Treatment Type

By End User

By Region

  • Gastric Neuroendocrine Tumours

  • Lung Neuroendocrine Tumours

  • Pancreatic Neuroendocrine Tumours

  • Appendiceal Neuroendocrine Tumors

  • Somatostatin Analogs

  • Targeted Therapy

    • Tyrosine Kinase Inhibitors

    • mTOR Inhibitors

  • Chemotherapy

    • Antimetabolites

    • Alkylating Agents

    • Natural Products

  • Hospital

  • Clinics

  • Oncology Centres

  • Ambulatory Surgery Centres

  • North America

  • Western Europe

  • Eastern Europe

  • Asia Pacific excluding Japan (APEJ)

  • Japan

  • Latin America

  • Middle East & Africa (MEA)

The research report on global neuroendocrine carcinoma market covers analysis on key companies dealing with neuroendocrine carcinoma. Various aspects such as SWOT analysis, key developments, innovations, product portfolio, financials and company overview are included in this section of the report. The reader can gain intelligence on the major players that have a good hold in the market, based on which new strategies can be devised to gain an edge on the competition. The weighted market analysis on global neuroendocrine carcinoma market delivers value to the reader by providing drinkable insights, ready to use statistical analysis and recommendations without biasness in order to plan future expansion strategies and also to gain stability in the changing dynamics of the global market.

Neuroendocrine Carcinoma Market Reports - Table of Contents

1. Executive Summary

A gist of the report, highlighting the key takeaways

1.1. Market Overview

1.2. Market Analysis

1.3. FMI Analysis and Recommendations

1.4. Wheel of Fortune

2. Market Introduction

A definition of Neuroendocrine Carcinoma market taxonomy

2.1. Market Taxonomy

2.2. Market Definition

2.3. Market Overview

3. Neuroendocrine Carcinoma Market View Point

3.1. Macro-Economic Factors 

3.2. Opportunity Analysis

3.3. Neuroendocrine Carcinoma Pipeline Snapshot 

3.4. Neuroendocrine Carcinoma Reimbursement Scenario

3.5. Neuroendocrine Carcinoma Regulations

3.6. Neuroendocrine Carcinoma Epidemiology

4. North America Neuroendocrine Carcinoma Market Analysis 2012–2016 and Forecast 2017–2027

Analysis highlighting historical trends, current market value, and future projections on the basis of key segments

4.1. Introduction

4.2. Regional Market Dynamics

4.2.1. Drivers

4.2.2. Restraints

4.2.3. Trends

4.3. Historical Market Size (US$ Mn) By Country, 2012-2016

4.3.1. U.S.

4.3.2. Canada

4.4. Market Size (US$ Mn) Forecast By Country, 2017-2027

4.4.1. U.S.

4.4.2. Canada

4.5. Historical Market Size (US$ Mn) Analysis By Disease Indication Type , 2012–2016

4.5.1. Gastric Neuroendocrine Tumors

4.5.2. Lung Neuroendocrine Tumors

4.5.3. Pancreatic Neuroendocrine Tumors

4.5.4. Appendiceal Neuroendocrine Tumors

4.6. Market Size (US$ Mn) Forecast By Disease Indication Type , 2017–2027

4.6.1. Gastric Neuroendocrine Tumors

4.6.2. Lung Neuroendocrine Tumors

4.6.3. Pancreatic Neuroendocrine Tumors

4.6.4. Appendiceal Neuroendocrine Tumors

4.7. Historical Market Size (US$ Mn) Analysis By Treatment Type , 2012–2016

4.7.1. Chemotherapy 

4.7.2. Antimetabolites

4.7.3. Alkylating agents

4.7.4. Natural Products

4.7.5. Targeted Therapy

4.7.6. Tyrosine Kinase Inhibitor

4.7.7. mTOR Inhibitor

4.7.8. Somatostatin Analogs 

4.8. Market Size (US$ Mn) and Forecast, By Treatment Type , 2017–2027

4.8.1. Chemotherapy 

4.8.2. Antimetabolites

4.8.3. Alkylating agents

4.8.4. Natural Products

4.8.5. Targeted Therapy

4.8.6. Tyrosine Kinase Inhibitor

4.8.7. mTOR Inhibitor

4.8.8. Somatostatin Analogs 

4.9. Historical Market Size (US$ Mn) Analysis By End User , 2012–2016

4.9.1. Hospitals

4.9.2. Clinics

4.9.3. Oncology Centers 

4.9.4. Ambulatory Surgery Centers 

4.10. Market Size (US$ Mn) and Forecast, By End User , 2017–2027

4.10.1. Hospitals

4.10.2. Clinics

4.10.3. Oncology Centers 

4.10.4. Ambulatory Surgery Centers  

4.11. Market Attractiveness Analysis

4.11.1. By Country

4.11.2. By Disease Indication Type    

4.11.3. By Treatment Type 

4.11.4. By End User 

4.12. Key Representative Market Participants

4.13. Key Participants Market Presence (Intensity Map)

5. Western Europe Neuroendocrine Carcinoma Market Analysis 2012–2016 and Forecast 2017–2027

Analysis highlighting historical trends, current market value, and future projections on the basis of key segments

5.1. Introduction

5.2. Regional Market Dynamics

5.2.1. Drivers

5.2.2. Restraints

5.2.3. Trends

5.3. Historical Market Size (US$ Mn) By Country, 2012-2016

5.3.1. Germany

5.3.2. United Kingdom

5.3.3. France

5.3.4. Italy

5.3.5. Spain

5.3.6. Rest of Western Europe

5.4. Market Size (US$ Mn) Forecast By Country, 2017-2027

5.4.1. Germany

5.4.2. United Kingdom

5.4.3. France

5.4.4. Italy

5.4.5. Spain

5.4.6. Rest of Western Europe

5.5. Historical Market Size (US$ Mn) Analysis By Disease Indication Type , 2012–2016

5.5.1. Gastric Neuroendocrine Tumors

5.5.2. Lung Neuroendocrine Tumors

5.5.3. Pancreatic Neuroendocrine Tumors

5.5.4. Appendiceal Neuroendocrine Tumors

5.6. Market Size (US$ Mn) Forecast By Disease Indication Type , 2017–2027

5.6.1. Gastric Neuroendocrine Tumors

5.6.2. Lung Neuroendocrine Tumors

5.6.3. Pancreatic Neuroendocrine Tumors

5.6.4. Appendiceal Neuroendocrine Tumors

5.7. Historical Market Size (US$ Mn) Analysis By Treatment Type , 2012–2016

5.7.1. Chemotherapy 

5.7.2. Antimetabolites

5.7.3. Alkylating agents

5.7.4. Natural Products

5.7.5. Targeted Therapy

5.7.6. Tyrosine Kinase Inhibitor

5.7.7. mTOR Inhibitor

5.7.8. Somatostatin Analogs 

5.8. Market Size (US$ Mn) and Forecast, By Treatment Type , 2017–2027

5.8.1. Chemotherapy 

5.8.2. Antimetabolites

5.8.3. Alkylating agents

5.8.4. Natural Products

5.8.5. Targeted Therapy

5.8.6. Tyrosine Kinase Inhibitor

5.8.7. mTOR Inhibitor

5.8.8. Somatostatin Analogs 

5.9. Historical Market Size (US$ Mn) Analysis By End User , 2012–2016

5.9.1. Hospitals

5.9.2. Clinics

5.9.3. Oncology Centers 

5.9.4. Ambulatory Surgery Centers 

5.10. Market Size (US$ Mn) and Forecast, By End User , 2017–2027

5.10.1. Hospitals

5.10.2. Clinics

5.10.3. Oncology Centers 

5.10.4. Ambulatory Surgery Centers  

5.11. Market Attractiveness Analysis

5.11.1. By Country

5.11.2. By Disease Indication Type    

5.11.3. By Treatment Type 

5.11.4. By End User 

5.12. Key Representative Market Participants

5.13. Key Participants Market Presence (Intensity Map)

6. Eastern Europe Neuroendocrine Carcinoma Market Analysis 2012–2016 and Forecast 2017–2027

Analysis highlighting historical trends, current market value, and future projections on the basis of key segments

6.1. Introduction

6.2. Regional Market Dynamics

6.2.1. Drivers

6.2.2. Restraints

6.2.3. Trends

6.3. Historical Market Size (US$ Mn) By Country, 2012-2016

6.3.1. Russia

6.3.2. Poland

6.3.3. Rest of Eastern Europe

6.4. Market Size (US$ Mn) Forecast By Country, 2017-2027

6.4.1. Russia

6.4.2. Poland

6.4.3. Rest of Eastern Europe

6.5. Historical Market Size (US$ Mn) Analysis By Disease Indication Type , 2012–2016

6.5.1. Gastric Neuroendocrine Tumors

6.5.2. Lung Neuroendocrine Tumors

6.5.3. Pancreatic Neuroendocrine Tumors

6.5.4. Appendiceal Neuroendocrine Tumors

6.6. Market Size (US$ Mn) Forecast By Disease Indication Type , 2017–2027

6.6.1. Gastric Neuroendocrine Tumors

6.6.2. Lung Neuroendocrine Tumors

6.6.3. Pancreatic Neuroendocrine Tumors

6.6.4. Appendiceal Neuroendocrine Tumors

6.7. Historical Market Size (US$ Mn) Analysis By Treatment Type , 2012–2016

6.7.1. Chemotherapy 

6.7.2. Antimetabolites

6.7.3. Alkylating agents

6.7.4. Natural Products

6.7.5. Targeted Therapy

6.7.6. Tyrosine Kinase Inhibitor

6.7.7. mTOR Inhibitor

6.7.8. Somatostatin Analogs 

6.8. Market Size (US$ Mn) and Forecast, By Treatment Type , 2017–2027

6.8.1. Chemotherapy 

6.8.2. Antimetabolites

6.8.3. Alkylating agents

6.8.4. Natural Products

6.8.5. Targeted Therapy

6.8.6. Tyrosine Kinase Inhibitor

6.8.7. mTOR Inhibitor

6.8.8. Somatostatin Analogs 

6.9. Historical Market Size (US$ Mn) Analysis By End User , 2012–2016

6.9.1. Hospitals

6.9.2. Clinics

6.9.3. Oncology Centers 

6.9.4. Ambulatory Surgery Centers 

6.10. Market Size (US$ Mn) and Forecast, By End User , 2017–2027

6.10.1. Hospitals

6.10.2. Clinics

6.10.3. Oncology Centers 

6.10.4. Ambulatory Surgery Centers  

6.11. Market Attractiveness Analysis

6.11.1. By Country

6.11.2. By Disease Indication Type    

6.11.3. By Treatment Type 

6.11.4. By End User 

6.12. Key Representative Market Participants

6.13. Key Participants Market Presence (Intensity Map)

7. Latin America Neuroendocrine Carcinoma Market Analysis 2012–2016 and Forecast 2017–2027

Analysis highlighting historical trends, current market value, and future projections on the basis of key segments

7.1. Introduction

7.2. Regional Market Dynamics

7.2.1. Drivers

7.2.2. Restraints

7.2.3. Trends

7.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016

7.3.1. Brazil

7.3.2. Mexico

7.3.3. Rest of Latin America

7.4. Market Size (US$ Mn) Forecast By Country, 2017–2027

7.4.1. Brazil

7.4.2. Mexico

7.4.3. Rest of Latin America

7.5. Historical Market Size (US$ Mn) Analysis By Disease Indication Type , 2012–2016

7.5.1. Gastric Neuroendocrine Tumors

7.5.2. Lung Neuroendocrine Tumors

7.5.3. Pancreatic Neuroendocrine Tumors

7.5.4. Appendiceal Neuroendocrine Tumors

7.6. Market Size (US$ Mn) Forecast By Disease Indication Type , 2017–2027

7.6.1. Gastric Neuroendocrine Tumors

7.6.2. Lung Neuroendocrine Tumors

7.6.3. Pancreatic Neuroendocrine Tumors

7.6.4. Appendiceal Neuroendocrine Tumors

7.7. Historical Market Size (US$ Mn) Analysis By Treatment Type , 2012–2016

7.7.1. Chemotherapy 

7.7.2. Antimetabolites

7.7.3. Alkylating agents

7.7.4. Natural Products

7.7.5. Targeted Therapy

7.7.6. Tyrosine Kinase Inhibitor

7.7.7. mTOR Inhibitor

7.7.8. Somatostatin Analogs 

7.8. Market Size (US$ Mn) and Forecast, By Treatment Type , 2017–2027

7.8.1. Chemotherapy 

7.8.2. Antimetabolites

7.8.3. Alkylating agents

7.8.4. Natural Products

7.8.5. Targeted Therapy

7.8.6. Tyrosine Kinase Inhibitor

7.8.7. mTOR Inhibitor

7.8.8. Somatostatin Analogs 

7.9. Historical Market Size (US$ Mn) Analysis By End User , 2012–2016

7.9.1. Hospitals

7.9.2. Clinics

7.9.3. Oncology Centers 

7.9.4. Ambulatory Surgery Centers 

7.10. Market Size (US$ Mn) and Forecast, By End User , 2017–2027

7.10.1. Hospitals

7.10.2. Clinics

7.10.3. Oncology Centers 

7.10.4. Ambulatory Surgery Centers  

7.11. Market Attractiveness Analysis

7.11.1. By Country

7.11.2. By Disease Indication Type    

7.11.3. By Treatment Type 

7.11.4. By End User 

7.12. Key Representative Market Participants

7.13. Key Participants Market Presence (Intensity Map)

8. Asia Pacific Excluding Japan Neuroendocrine Carcinoma Market Analysis 2012–2016 and Forecast 2017–2027

Analysis highlighting historical trends, current market value, and future projections on the basis of key segments

8.1. Introduction

8.2. Regional Market Dynamics

8.2.1. Drivers

8.2.2. Restraints

8.2.3. Trends

8.3. Historical Market Size (US$ Mn) By Country, 2012-2016

8.3.1. China

8.3.2. India

8.3.3. Australia and New Zealand

8.3.4. ASEAN

8.3.5. Rest of APEJ

8.4. Market Size (US$ Mn) Forecast By Country, 2017-2027

8.4.1. China

8.4.2. India

8.4.3. Australia and New Zealand

8.4.4. ASEAN

8.4.5. Rest of APEJ

8.5. Historical Market Size (US$ Mn) Analysis By Disease Indication Type , 2012–2016

8.5.1. Gastric Neuroendocrine Tumors

8.5.2. Lung Neuroendocrine Tumors

8.5.3. Pancreatic Neuroendocrine Tumors

8.5.4. Appendiceal Neuroendocrine Tumors

8.6. Market Size (US$ Mn) Forecast By Disease Indication Type , 2017–2027

8.6.1. Gastric Neuroendocrine Tumors

8.6.2. Lung Neuroendocrine Tumors

8.6.3. Pancreatic Neuroendocrine Tumors

8.6.4. Appendiceal Neuroendocrine Tumors

8.7. Historical Market Size (US$ Mn) Analysis By Treatment Type , 2012–2016

8.7.1. Chemotherapy 

8.7.2. Antimetabolites

8.7.3. Alkylating agents

8.7.4. Natural Products

8.7.5. Targeted Therapy

8.7.6. Tyrosine Kinase Inhibitor

8.7.7. mTOR Inhibitor

8.7.8. Somatostatin Analogs 

8.8. Market Size (US$ Mn) and Forecast, By Treatment Type , 2017–2027

8.8.1. Chemotherapy 

8.8.2. Antimetabolites

8.8.3. Alkylating agents

8.8.4. Natural Products

8.8.5. Targeted Therapy

8.8.6. Tyrosine Kinase Inhibitor

8.8.7. mTOR Inhibitor

8.8.8. Somatostatin Analogs 

8.9. Historical Market Size (US$ Mn) Analysis By End User , 2012–2016

8.9.1. Hospitals

8.9.2. Clinics

8.9.3. Oncology Centers 

8.9.4. Ambulatory Surgery Centers 

8.10. Market Size (US$ Mn) and Forecast, By End User , 2017–2027

8.10.1. Hospitals

8.10.2. Clinics

8.10.3. Oncology Centers 

8.10.4. Ambulatory Surgery Centers  

8.11. Market Attractiveness Analysis

8.11.1. By Country

8.11.2. By Disease Indication Type    

8.11.3. By Treatment Type 

8.11.4. By End User 

8.12. Key Representative Market Participants

8.13. Key Participants Market Presence (Intensity Map)

9. Japan Neuroendocrine Carcinoma Market Analysis 2012–2016 and Forecast 2017–2027

Analysis highlighting historical trends, current market value, and future projections on the basis of key segments

9.1. Introduction

9.2. Regional Market Dynamics

9.2.1. Drivers

9.2.2. Restraints

9.2.3. Trends

9.3. Historical Market Size (US$ Mn) Analysis By Disease Indication Type , 2012–2016

9.3.1. Gastric Neuroendocrine Tumors

9.3.2. Lung Neuroendocrine Tumors

9.3.3. Pancreatic Neuroendocrine Tumors

9.3.4. Appendiceal Neuroendocrine Tumors

9.4. Market Size (US$ Mn) Forecast By Disease Indication Type , 2017–2027

9.4.1. Gastric Neuroendocrine Tumors

9.4.2. Lung Neuroendocrine Tumors

9.4.3. Pancreatic Neuroendocrine Tumors

9.4.4. Appendiceal Neuroendocrine Tumors

9.5. Historical Market Size (US$ Mn) Analysis By Treatment Type , 2012–2016

9.5.1. Chemotherapy 

9.5.2. Antimetabolites

9.5.3. Alkylating agents

9.5.4. Natural Products

9.5.5. Targeted Therapy

9.5.6. Tyrosine Kinase Inhibitor

9.5.7. mTOR Inhibitor

9.5.8. Somatostatin Analogs 

9.6. Market Size (US$ Mn) and Forecast, By Treatment Type , 2017–2027

9.6.1. Chemotherapy 

9.6.2. Antimetabolites

9.6.3. Alkylating agents

9.6.4. Natural Products

9.6.5. Targeted Therapy

9.6.6. Tyrosine Kinase Inhibitor

9.6.7. mTOR Inhibitor

9.6.8. Somatostatin Analogs 

9.7. Historical Market Size (US$ Mn) Analysis By End User , 2012–2016

9.7.1. Hospitals

9.7.2. Clinics

9.7.3. Oncology Centers 

9.7.4. Ambulatory Surgery Centers 

9.8. Market Size (US$ Mn) and Forecast, By End User , 2017–2027

9.8.1. Hospitals

9.8.2. Clinics

9.8.3. Oncology Centers 

9.8.4. Ambulatory Surgery Centers  

9.9. Market Attractiveness Analysis

9.9.1. By Country

9.9.2. By Disease Indication Type    

9.9.3. By Treatment Type 

9.9.4. By End User 

9.10. Key Representative Market Participants

9.11. Key Participants Market Presence (Intensity Map)

10. Middle East and Africa Neuroendocrine Carcinoma Market Analysis 2012–2016 and Forecast 2017–2027

Analysis highlighting historical trends, current market value, and future projections on the basis of key segments

10.1. Introduction

10.2. Regional Market Dynamics

10.2.1. Drivers

10.2.2. Restraints

10.2.3. Trends

10.3. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016

10.3.1. GCC Countries

10.3.2. South Africa

10.3.3. Rest of MEA

10.4. Market Size (US$ Mn) and Forecast By Country, , 2017–2027

10.4.1. GCC Countries

10.4.2. South Africa

10.4.3. Rest of MEA

10.5. Historical Market Size (US$ Mn) Analysis By Disease Indication Type , 2012–2016

10.5.1. Gastric Neuroendocrine Tumors

10.5.2. Lung Neuroendocrine Tumors

10.5.3. Pancreatic Neuroendocrine Tumors

10.5.4. Appendiceal Neuroendocrine Tumors

10.6. Market Size (US$ Mn) Forecast By Disease Indication Type , 2017–2027

10.6.1. Gastric Neuroendocrine Tumors

10.6.2. Lung Neuroendocrine Tumors

10.6.3. Pancreatic Neuroendocrine Tumors

10.6.4. Appendiceal Neuroendocrine Tumors

10.7. Historical Market Size (US$ Mn) Analysis By Treatment Type , 2012–2016

10.7.1. Chemotherapy 

10.7.2. Antimetabolites

10.7.3. Alkylating agents

10.7.4. Natural Products

10.7.5. Targeted Therapy

10.7.6. Tyrosine Kinase Inhibitor

10.7.7. mTOR Inhibitor

10.7.8. Somatostatin Analogs 

10.8. Market Size (US$ Mn) and Forecast, By Treatment Type , 2017–2027

10.8.1. Chemotherapy 

10.8.2. Antimetabolites

10.8.3. Alkylating agents

10.8.4. Natural Products

10.8.5. Targeted Therapy

10.8.6. Tyrosine Kinase Inhibitor

10.8.7. mTOR Inhibitor

10.8.8. Somatostatin Analogs 

10.9. Historical Market Size (US$ Mn) Analysis By End User , 2012–2016

10.9.1. Hospitals

10.9.2. Clinics

10.9.3. Oncology Centers 

10.9.4. Ambulatory Surgery Centers 

10.10. Market Size (US$ Mn) and Forecast, By End User , 2017–2027

10.10.1. Hospitals

10.10.2. Clinics

10.10.3. Oncology Centers 

10.10.4. Ambulatory Surgery Centers  

10.11. Market Attractiveness Analysis

10.11.1. By Country

10.11.2. By Disease Indication Type    

10.11.3. By Treatment Type 

10.11.4. By End User 

10.12. Key Representative Market Participants

10.13. Key Participants Market Presence (Intensity Map)

11. Forecast Factors: Relevance and Impact

12. Forecast Assumptions

13. Competition Landscape

Profile of some of the key market players, with specific focus on business and product strategy

13.1. Market Structure

13.2. Competition Dashboard

13.3. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)

13.3.1. Pfizer Inc. 

13.3.2. Novartis AG 

13.3.3. Chiasma Inc. 

13.3.4. Ipsen 

13.3.5. Abbvie Inc. 

13.3.6. Valeant Pharmaceuticals International Inc. 

13.3.7. Jubilant Life Sciences Ltd. 

13.3.8. Teva Pharmaceutical Industries Ltd 

13.3.9. F.Hoffmann-La Roche Ltd 

13.3.10. Advanced Accelerator Applications  

13.3.11. Mateon Therapeutics, Inc. 

13.3.12. Lexicon Pharmaceuticals, Inc. 

13.3.13. Isotopen Technologien München AGGlobal 

13.3.14. Hutchison China MediTech Ltd 

13.3.15. Amgen Inc 

13.3.16. Celgene Corporation 

13.3.17. Mallinckrodt plc. 

13.3.18. Dauntless Pharmaceuticals, Inc. 

14. Global Neuroendocrine Carcinoma Market Analysis 2012–2016 and Forecast 2017–2027, By Region

14.1. Introduction / Key Findings

14.2. Historical Market Size (US$ Mn) By Region

14.2.1. North America

14.2.2. Western Europe

14.2.3. Eastern Europe

14.2.4. Latin America

14.2.5. Asia Pacific Excluding Japan

14.2.6. Japan

14.2.7. Middle East and Africa

14.3. Market Size (US$ Mn) Forecast By Region

14.3.1. North America

14.3.2. Western Europe

14.3.3. Eastern Europe

14.3.4. Latin America

14.3.5. Asia Pacific Excluding Japan

14.3.6. Japan

14.3.7. Middle East and Africa

14.4. Market Attractiveness Analysis By Region

15. Global Neuroendocrine Carcinoma Market Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication Type   

15.1. Introduction

15.2. Historical Market Size (US$ Mn) Analysis By Disease Indication Type , 2012–2016

15.2.1. Gastric Neuroendocrine Tumors

15.2.2. Lung Neuroendocrine Tumors

15.2.3. Pancreatic Neuroendocrine Tumors

15.2.4. Appendiceal Neuroendocrine Tumors

15.3. Market Size (US$ Mn) Forecast By Disease Indication Type , 2017–2027

15.3.1. Gastric Neuroendocrine Tumors

15.3.2. Lung Neuroendocrine Tumors

15.3.3. Pancreatic Neuroendocrine Tumors

15.3.4. Appendiceal Neuroendocrine Tumors

15.4. Market Attractiveness Analysis By Disease Indication Type   

16. Global Neuroendocrine Carcinoma Market Analysis 2012–2016 and Forecast 2017–2027, By Treatment Type 

16.1. Introduction

16.2. Historical Market Size (US$ Mn) Analysis By Treatment Type , 2012–2016

16.2.1. Chemotherapy 

16.2.2. Antimetabolites

16.2.3. Alkylating agents

16.2.4. Natural Products

16.2.5. Targeted Therapy

16.2.6. Tyrosine Kinase Inhibitor

16.2.7. mTOR Inhibitor

16.2.8. Somatostatin Analogs 

16.3. Market Size (US$ Mn) and Forecast, By Treatment Type , 2017–2027

16.3.1. Chemotherapy 

16.3.2. Antimetabolites

16.3.3. Alkylating agents

16.3.4. Natural Products

16.3.5. Targeted Therapy

16.3.6. Tyrosine Kinase Inhibitor

16.3.7. mTOR Inhibitor

16.3.8. Somatostatin Analogs 

16.4. Market Attractive Analysis By End User 

17. Global Neuroendocrine Carcinoma Market Analysis 2012–2016 and Forecast 2017–2027, By End User 

17.1. Introduction

17.2. Historical Market Size (US$ Mn) Analysis By End User , 2012–2016

17.2.1. Hospitals

17.2.2. Clinics

17.2.3. Oncology Centers 

17.2.4. Ambulatory Surgery Centers 

17.3. Market Size (US$ Mn) and Forecast, By End User , 2017–2027

17.3.1. Hospitals

17.3.2. Clinics

17.3.3. Oncology Centers 

17.3.4. Ambulatory Surgery Centers 

17.4. Market Attractive Analysis By End User 

18. Global Neuroendocrine Carcinoma Market Analysis 2012–2016 and Forecast 2017–2027

18.1. Market Size and Y-o-Y Growth

18.2. Absolute $ Opportunity

19. Assumptions and Acronyms Used

A glossary of assumption and acronyms used in the report

20. Research Methodology

Neuroendocrine Carcinoma Market Reports - List of Tables

Table 01: North America Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country

Table 02: North America Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication Type

Table 03: North America Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Treatment Type

Table 04: North America Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By End User

Table 05: Western Europe Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country

Table 06: Western Europe Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication Type

Table 07: Western Europe Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Treatment Type

Table 08: Western Europe Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By End User

Table 09: Eastern Europe  Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country

Table 10: Eastern Europe  Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication Type

Table 11: Eastern Europe  Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Treatment Type

Table 12: Eastern Europe  Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By End User

Table 13: APEJ Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country

Table 14: APEJ Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication Type

Table 15: APEJ Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Treatment Type

Table 16: APEJ Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By End User

Table 17: Japan Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication Type

Table 18: Japan Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Treatment Type

Table 19: Japan Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By End User

Table 20: Latin America Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country

Table 21: Latin America Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication Type

Table 22: Latin America Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Treatment Type

Table 23: Latin America Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By End User

Table 24: MEA Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country

Table 25: MEA Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication Type

Table 26: MEA Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Treatment Type

Table 27: MEA Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By End User

Table 28: Global Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication Type

Table 29: Global Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication Type

Table 30: Global Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Treatment Type

Table 31: Global Neuroendocrine Carcinoma Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By End User

Neuroendocrine Carcinoma Market Reports - List of Figures

Figure 01: North America Neuroendocrine Carcinoma Market Size Analysis, 2012-2016

Figure 02: North America Neuroendocrine Carcinoma Market Forecast, 2017–2027

Figure 03: North America Neuroendocrine Carcinoma Market Attractiveness Analysis, By Disease Indication Type

Figure 04: North America Neuroendocrine Carcinoma Market Attractiveness Analysis, By Treatment Type

Figure 05: North America Neuroendocrine Carcinoma Market Attractiveness Analysis, By End User 

Figure 06: Latin America Neuroendocrine Carcinoma Market Attractiveness Analysis By Country, 2017–2025

Figure 07: Western Europe Neuroendocrine Carcinoma Market Size Analysis, 2012-2016

Figure 08: Western Europe Neuroendocrine Carcinoma Market Forecast, 2017–2027

Figure 09: Western Europe Neuroendocrine Carcinoma Market Attractiveness Analysis, By Disease Indication Type

Figure 10: Western Europe Neuroendocrine Carcinoma Market Attractiveness Analysis, By Treatment Type

Figure 11: Western Europe Neuroendocrine Carcinoma Market Attractiveness Analysis, By End User 

Figure 12: Latin America Neuroendocrine Carcinoma Market Attractiveness Analysis By Country, 2017–2025

Figure 13: Eastern Europe  Neuroendocrine Carcinoma Market Size Analysis, 2012-2016

Figure 14: Eastern Europe  Neuroendocrine Carcinoma Market Forecast, 2017–2027

Figure 15: North America Neuroendocrine Carcinoma Market Attractiveness Analysis, By Disease Indication Type

Figure 16: North America Neuroendocrine Carcinoma Market Attractiveness Analysis, By Treatment Type

Figure 17: North America Neuroendocrine Carcinoma Market Attractiveness Analysis, By End User 

Figure 18: Latin America Neuroendocrine Carcinoma Market Attractiveness Analysis By Country, 2017–2025

Figure 19: APEJ Neuroendocrine Carcinoma Market Size Analysis, 2012-2016

Figure 20: APEJ Neuroendocrine Carcinoma Market Forecast, 2017–2027

Figure 21: APEJ Neuroendocrine Carcinoma Market Attractiveness Analysis, By Disease Indication Type

Figure 22: APEJ Neuroendocrine Carcinoma Market Attractiveness Analysis, By Treatment Type

Figure 23: APEJ Neuroendocrine Carcinoma Market Attractiveness Analysis, By End User 

Figure 24: Latin America Neuroendocrine Carcinoma Market Attractivenesas Analysis By Country, 2017–2025

Figure 25: Japan Neuroendocrine Carcinoma Market Size Analysis, 2012-2016

Figure 26: Japan Neuroendocrine Carcinoma Market Forecast, 2017–2027

Figure 27: Japan Neuroendocrine Carcinoma Market Attractiveness Analysis, By Disease Indication Type

Figure 28: Japan Neuroendocrine Carcinoma Market Attractiveness Analysis, By Treatment Type

Figure 29: Japan Neuroendocrine Carcinoma Market Attractiveness Analysis, By End User 

Figure 30: Latin America Neuroendocrine Carcinoma Market Size Analysis, 2012-2016

Figure 31: Latin America Neuroendocrine Carcinoma Market Forecast, 2017–2027